Reactive vaccination of workplaces and schools against COVID-19

Benjamin Faucher[1], Rania Assab[1], Jonathan Roux[2], Daniel Levy-Bruhl[3], Cécile Tran Kiem[4,5],

Simon Cauchemez[4], Laura Zanetti[6], Vittoria Colizza[1], Pierre-Yves Boëlle[1], Chiara Poletto[1]

[1]INSERM, Sorbonne Université, Pierre Louis Institute of Epidemiology and Public Health, Paris, France

[2]Univ Rennes, EHESP, REPERES « Recherche en Pharmaco-Epidémiologie et Recours aux Soins » – EA 7449,

15 avenue du Professeur-Léon-Bernard, CS 74312, 35043 Rennes, France

[3]Santé Publique France, Saint Maurice, France

[4]Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, UMR2000, CNRS, Paris, France

[5]Collège Doctoral, Sorbonne Université, Paris, France

[6]Haute Autorité de Santé, Saint-Denis, France

Corresponding author: Chiara Poletto (chiara.poletto@inserm.fr)

Abstract

As vaccination against COVID-19 stalls in some countries, increased accessibility and more adaptive approaches may be useful to keep the epidemic under control. Here we study the impact of reactive vaccination targeting schools and workplaces where cases have been detected, with an agent-based model accounting for COVID-19 natural history, vaccine characteristics, individuals' demography and behaviour and social distancing. We study epidemic scenarios ranging from sustained spread to flare-up of cases, and we consider reactive vaccination alone and in combination with mass vaccination. With the same number of doses, reactive vaccination reduces cases more than non-reactive approaches, but may require concentrating a high number of doses over a short time in case of sustained spread. In case of flare-ups, quick implementation of reactive vaccination supported by enhanced test-trace-isolate practices would limit further spread. These results provide key information to promote an adaptive vaccination plan in the months to come.

Introduction

Achieving high vaccination coverage against COVID-19 is now the main strategy to reduce disease burden and pressure on health care organisations and to lift non-pharmaceutical interventions (NPI). To this end, mass vaccination campaigns started in Western countries mainly prioritising health care workers and groups more at risk of severe infection [1–4] – i.e. the elderly and those with comorbidities. However, now that vaccination has been opened to all adults, vaccine uptake remains below needs - e.g. in France, the United States - due to logistical issues, vaccine accessibility and/or hesitancy. With cases on the rise again due to the emergence of new viral variants, vaccine delivery must become more adaptive in response to the epidemic situation. For instance, it could preferentially target people at higher risk of infection, e.g. because attending places where more cases are reported. As people who are hesitant to vaccinate are more likely to accept vaccination when the perceived risk of infection is higher [5], this would help overcome barriers to vaccination [6].

Hotspot vaccination, which involves redirecting vaccine supplies to geographic areas of highest incidence, is already part of some European countries' plans to combat the emergence of variant Delta [6]. But other reactive vaccination schemes are possible, such as ring vaccination that targets contacts of confirmed cases or contacts of those contacts, or vaccination in workplaces or schools where cases have been detected. This could potentially improve vaccine impact by preventing transmission where it is active and even enable the efficient management of flare-ups. For outbreaks of smallpox or Ebola fever, ring vaccination has proved effective to rapidly curtail the spread of cases [7–10]. However, the experience of these past epidemics cannot be transposed directly to COVID-19 due to the many differences in the infection characteristics and epidemiological context. For example, COVID-19 cases are infectious a few days before symptom onset [11], but generally detected a few days later. This means they may have had time to infect their direct contacts, potentially limiting the efficacy of ring vaccination. Vaccinating an extended network of contacts, as could be done with the vaccination of whole workplaces or schools, could have a larger impact, especially if adopted in combination with strengthened protective measures to slow down transmission, such as masks, physical distancing, and contact tracing. This could be feasible in many countries, leveraging the established test-trace-isolate (TTI) system that enables prompt detection of clusters of cases to inform where vaccines should be deployed. Properly assessing the interest of reactive vaccination therefore requires to consider in detail the interactions of vaccine characteristics, pace of vaccination, COVID-19 natural history, case detection practices and overall changes in human contact behaviour.

We therefore extend an agent-based model that has been previously described [12] to quantify

the impact of a reactive vaccination strategy targeting workplaces, universities and 18+ years

old in high schools where cases have been detected. We compare the impact of reactive

vaccination with non-reactive vaccination in similar settings or with mass vaccination, and test

these strategies alone and in combination. We explore differences in vaccine availability and

logistic constraints, and assess the influence of the dynamic of the epidemic (low/high

incidence, new emerging variant) and different stages of the vaccination campaign.

Results

COVID-19 vaccination strategies targeting workplaces and schools

We extend a previously described SARS-CoV-2 transmission model [12] to simulate vaccine

administration, running in parallel with other interventions - i.e. contact tracing, telework and

social restrictions. Following similar approaches [13–16], the model is stochastic and individual

based. It takes as input a synthetic population reproducing demographic, social-contact

information, workplace sizes and school types (Figure 1A) of a typical medium-sized French

town (117,492 inhabitants). Contacts are described as a dynamic multi-layer network [12]

(Figure 1B).

We assume that the vaccine reduced susceptibility, quantified by the vaccine efficacy VE_S,

and symptomatic illness after infection, quantified by VE_{SP} [17] (Figure 1C). The vaccine-

induced protection is described based on the characteristics of mRNA vaccines [18,19] with no

protection up to 1 week after inoculation, intermediate protection after 1 week ($VE_{S,1} = 52\%$

and $VE_{SP,1} = 62\%$), and maximum protection after 2 weeks ($VE_{S,2} = 87\%$ and $VE_{SP,2} =$

90%).

Figure 1. A Distribution of workplace size and of school type for the municipality of Metz (Grand East region, France), used in the simulation study. **B** Schematic representation of the population structure, the reactive vaccination and contact tracing. The synthetic population is represented as a dynamic multi-layer network, where layers encode contacts in household, workplace, school, community and transport. In the figure, school and workplace layers are collapsed and community and transport are not displayed for the sake of visualisation. Nodes repeatedly appear on both the household and the workplace/school layer. The identification of an infectious individual (in purple in the figure) triggers the detection and isolation of his/her contacts (nodes with orange border) and the vaccination of individuals attending the same workplace/school and belonging to the same household who accept to be vaccinated (green). **C** Compartmental model of COVID-19 transmission and vaccination. Description of the compartments is reported on the Methods section. **D** Timeline of events following infection for a case that is detected in a scenario with reactive vaccination. For panels C, D transition rate parameters and their values are described in the Methods and in the Supplementary Information.

To parametrise the epidemiological context, we assume 26% [20,21] of the population was fully

immune to the virus and the reproductive ratio is $R = 1.2$, in the range of values estimated

during the ascending phase of winter 20-21/spring 2021 epidemic waves [22]. We model the

baseline TTI policy after the French situation, allowing 3.6 days on average from symptoms

onset to detection and 2.8 average contacts detected and isolated per index case [23] (Figure 1
D). We assume that 50% of clinical cases and 10% of subclinical cases are detected.
Scenarios with enhanced TTI are described later in the text.

We then model vaccination of 18+ years old population assuming vaccination uptake is
bounded above by vaccine acceptance, set to 66% in the 18-65 years old and 90% in the
over 65 years old at baseline, based on surveys conducted on the French population [24].
When the vaccine is proposed in the context of reactive vaccination, we also consider uptake
up to 100%. We model a *reactive vaccination* strategy, where the detection of a case thanks
to TTI triggers the vaccination of household members and those in the same workplace or
school (Figure 1D). In this scenario, a delay of 2 days on average is assumed between the
detection of the case and vaccination to account for logistical issues - i.e. ~5.6 days on
average from the index case's symptoms onset. We also model three *non-reactive*
vaccination strategies, i.e. i) where vaccination is deployed randomly throughout the mass
vaccination program (*mass*) or ii) in school sites (*school location*) or iii)
workplaces/universities (*workplaces/universities*) chosen at random, up to the maximum
number of doses available daily. In the school location vaccination, we assume vaccine sites
are created in relation with schools to vaccinate pupils and their household members who are
above 18 years old. The impact of these strategies is evaluated based on the comparison
with a reference scenario, where no vaccination campaign is conducted during the course of
the simulation and vaccination coverage remains at its initial level.

Comparison between reactive and non-reactive vaccination strategies

In Figure 2 we compare all strategies, assuming that vaccine uptake is the same in reactive
and non-reactive vaccination as reference, and initial vaccination coverage among adults is
small, i.e. 13% of the [18,60] group. During the course of the simulation we consider daily
first-dose vaccination rates for non-reactive strategies between 85 first doses per 100,000
inhabitants (corresponding to the initial vaccination capacity in France in January/February
2021) and 512 first doses per 100,000 inhabitants (close to highest vaccination capacity
values reached in May/June 2021 before it declined in June). Panels A-C show the results for
a *high incidence* scenario, here defined by initial incidence at ~160 clinical cases weekly per
100,000 inhabitants - close to values registered during the first half of May 2021 in France.
Panel A shows the relative reduction in the attack rate after two months as a function of the
number of first daily doses, while Figure 2B compares the incidence profiles under different
strategies at a similar number of vaccine doses. The mass, school location and
workplaces/universities strategies have a similar impact on the epidemic. They lead to a
reduction between 3.6% and 4.9% of the attack rate, when 85 first doses per 100,000

inhabitants are administered each day, and between 20% and 22% with 511 per 100,000
inhabitants. Among the three, mass vaccination has the lowest impact. This is because the
workplaces/universities and school location strategies target a portion of the population with
more contacts - working population, or population living in large households - with a greater
potential to transmit the infection. Compared with each of the three strategies, reactive
vaccination produces a stronger reduction in cases at equal number of doses in the two-
month period, i.e. a reduction of 24.5% with the number of first-dose vaccinations being 247
per 100,000 inhabitants each day on average.

In panel C we show the number of first doses in time and the number of places to vaccinate -
as a proxy to the incurred costs of vaccine deployment. The number of daily inoculated doses
is initially high, with 1112 doses per 100,000 inhabitants used in a day at the peak of vaccine
demand, but declines rapidly afterwards down to 86 doses. More than 10 workplaces/schools
(0.3% of workplaces and eligible schools of the municipality considered) would need to be
vaccinated each day at the peak of vaccine demand.

Figure 2. **A- D** High incidence scenario, with initial weekly incidence of clinical cases ~160 per 100,000
inhabitants. **A** Relative reduction (RR) in the attack rate (AR) over the first two months for all strategies as a
function of the vaccination pace. RR is computed as $(AR_{ref} - AR)/AR_{ref}$ where AR_{ref} is the AR of the reference
scenario, with initial vaccination only. AR is computed from clinical cases. **B** Incidence of clinical cases with
different vaccination strategies. The grey curve indicates the reference scenario. The non-reactive scenarios
plotted are obtained with 255 new daily vaccinations per 100,000 inhabitants. In the reactive vaccination the
average pace is 247 new daily vaccinations per 100,000 inhabitants. **C** Number of daily first-dose vaccinations,
and workplaces/schools (WP/S in the plot) where vaccines are deployed. **D-F** Same as A-C for the low incidence

scenario with initial incidence of clinical cases 5 per 100,000 inhabitants. In panel E, the vaccination pace is 85
and 46 daily first-dose vaccinations per 100,000 inhabitants for the non-reactive and reactive strategies,
respectively. In all cases we assumed the following parameters: R=1.2; Initial immunity 26%; vaccinated at the
beginning 81% and 13% for 60+ and <60, respectively; 20% of individuals are doing teleworking and 30% of
community contacts are removed. Values are means over 2000 stochastic simulations, error bars in panels A and
D are derived from the standard errors of the AR. Error bars in panels B, C, E, F, are not displayed for the sake of
visualisation.

In Figure 2 D-F we consider a *low incidence* scenario, i.e. 5 clinical cases weekly per 100,000
inhabitants. In this scenario, reactive vaccination yields a relative reduction in the attack rate
that is twice the one produced by the workplaces/universities strategy with 85 daily doses per
100,000 inhabitants, but only using 46 daily doses per 100,000 on average in the two-months
period. The deployment of vaccines and the number of workplaces/schools to vaccinate is
initially low and increases gradually with incidence.

We have considered so far specific scenarios in terms of epidemiological and vaccine
parameters. In the Supplementary Information we explore alternative values of key
parameters, e.g. initial incidence, transmission, immunity level of the population, fraction of
adults initially vaccinated, reduction in contacts due to social distancing, vaccine efficacy and
time needed for the vaccine to become effective. In particular, we explore a reduction in
vaccine efficacy of 30% and a longer time needed for the vaccine protection to mount -
parameterized according to [25]. In varying these parameters, the overall effectiveness of
vaccination, regardless of the strategy, changes. However, reactive vaccination remains in all
cases the most effective strategy when the comparison is done at equal number of doses. We
also tested the robustness of our results according to the selected health outcome, using
hospitalisations, ICU admissions, ICU bed occupancy, deaths, life-years lost and quality-
adjusted life-years lost, finding the same qualitative behaviour.

**186 Combined reactive and mass vaccination for managing sustained COVID-19
spread**

With high availability of vaccine doses, reactive vaccination could be deployed on top of mass
vaccination. We consider first the high incidence scenario defined in the previous section and
compare mass and reactive vaccination simultaneously (*combined strategy*) with mass
vaccination alone. We focus on the first two months since the implementation of the
vaccination strategy. At an equal number of doses within the period, the combined strategy
outperforms mass vaccination in reducing the attack rate. For instance, the relative reduction
in the attack rate would go from 18%, when 448 daily doses per 100,000 inhabitants are

deployed for mass vaccination, to 29%, when the same number of doses are used for

reactive and mass vaccination combined (Figure 3A).

We explore alternative scenarios where the number of vaccines used and places vaccinated

are limited due to availability and logistic constraints. We assess the effect of three

parameters: (i) the maximum daily number of vaccines that can be allocated towards reactive

vaccination (with caps going from 85 to 512 per 100,000 inhabitants, compared with unlimited

vaccine availability assumed in the baseline scenario), (ii) the time from the detection of a

case and the vaccine deployment (set to 2 days in the baseline scenario, and here explored

between 1 and 4 days), and (iii) the number of detected cases that triggers vaccination in a

place (from 2 to 5 cases, vs. the baseline value of 1).The number of first-dose vaccinations in

time under the different caps is plotted in Figure 3B. A small cap on the number of doses

limits the impact of the reactive strategy. Figure 3C shows that the attack rate relative

reduction drops from 21% to 8.2% if only a maximum of 85 first doses per 100,000

inhabitants daily can be used in reactive vaccination. However, the inclusion of reactive

vaccination is beneficial (i.e. RR is above the mass strategy only with a similar number of

doses) as soon as the cap in the number of doses is higher than 85 per 100,000 inhabitants.

Doubling the time required to start reactive vaccination, from 2 days to 4 days, has a limited

effect on the reduction of the AR (relative reduction reduced from 29% to 27%, Figure 3D).

Increasing the number of detected cases used to trigger vaccination to 2 (respectively 5)

reduces the relative reduction to 22% (respectively 15%) (Figure 3E).

We so far assumed that vaccine uptake is the same in mass and reactive vaccination. In

Figure 3F we consider a scenario where vaccine uptake with reactive vaccination climbs to

100%. Attack rate relative reduction increases in this case from 29% to 37%, with a demand

of 604 daily doses per 100,000 inhabitants on average.

Figure 3. **A** Relative reduction (RR) in the attack rate (AR) over the first two months for the combined strategy (mass + reactive) and the mass strategy with the same number of first-dose vaccinations as in the combined strategy during the period. RR is computed with respect to the reference scenario with initial vaccination only, as in Figure 2. Combined strategy is obtained by running in parallel the mass strategy - with 81, 170, and 255 daily vaccination rate per 100,000 inhabitants - and the reactive strategy. Number of doses displayed in the x-axis of the figure is the total number of doses used by the combined strategy. Corresponding incidence curves are reported in Figure S6 of Supplementary Information. **B** Number of first-dose vaccinations deployed each day for the combined strategy with different daily vaccines' capacity limits. **C, D, E** AR RR for the combined strategy as a function of the average daily number of first-dose vaccinations in the two-month period. Symbols of different colours indicate: (**C**) different values of daily vaccines' capacity limit; (**D**) different time from case detection to vaccine deployment; (**E**) different threshold size for the cluster to trigger vaccination. In panel C and E the curve corresponding to mass vaccination (the same one as in panel A) is also plotted as a guide to the eye. **F** Comparison between 100% and baseline vaccination uptake in case of reactive vaccination. In all cases we assumed the following parameters: R=1.2; Initial immunity 26%; vaccinated at the beginning 81% and 13% for 60+ and <60, respectively; 20% of individuals are doing teleworking and 30% of community contacts are removed. Values are means over 2000 stochastic simulations, error bars are derived from the standard errors of the AR.

Combined reactive and mass vaccination for managing a COVID-19 flare-up

We then quantify the impact of reactive vaccination on the management of a flare-up of cases, as possibly implemented upon detection of a new viral variant in the territory. We consider here a higher vaccination coverage among adults at the beginning (i.e. 33% of [18,60]) and no teleworking and social restrictions, similarly to what was observed in June

2021. A mass vaccination campaign with 512 first doses per day per 100,000 inhabitants is

underway from the start and baseline TTI is in place prior to cases' introduction. To start a

simulation, three infectious individuals are introduced in the population where the virus variant

is not currently circulating. Upon detection of the first case, we assume that TTI is enhanced,

finding 100% of clinical cases, 50% of subclinical cases and three times more contacts

outside the household with 100% compliance to isolation (Table S4 of the Supplementary

Information) - the scenario without TTI enhancement is also explored for comparison. As

soon as the number of detected cases reaches a predefined threshold, reactive vaccination is

started on top of the mass vaccination campaign. We assume vaccine uptake increases to

100% for reactive vaccination but stays at its baseline value for other approaches. In Figure

4A, B, C we quantify the probability of extinction and the average attack rate. We compare

the combined scenario with mass vaccination alone at an equal number of doses, and we

investigate starting the reactive vaccination after 1, 5 or 10 detected cases.

With enhanced TTI and 100% uptake for reactive vaccination starting from the first detected

case, the probability of extinction would increase (from 0.41 to 0.45) and the attack rate

decrease (from 41 to 34 cases per 100 000 inhabitants), compared with the mass scenario.

The added value of reactive vaccination would decrease if more detected cases are required

to start the intervention. We consider a similar level of uptake for reactive vaccination and

mass vaccination, finding no advantage of reactive vaccination in this case. Assuming no

enhancement in TTI occurs after the detection of the first case, we find no effect of the

reactive vaccination in disease containment, irrespective of the level of vaccination uptake.

Instead, the effect of the strategy on the reduction in attack rate is qualitatively similar to the

enhanced TTI case.

Figure 4 **A** Probability of extinction for an outbreak starting with three cases according to the measure

implemented. Four vaccination strategies are compared: mass only, combined where the reactive vaccination

starts at the detection of 1, 5, 10 cases (Combined cl. size= 1, 5, 10 in the figure). Four scenarios are compared,

considering both baseline and 100% uptake for reactive vaccination, and both baseline and enhanced TTI after

the detection of the first case. Probability of extinction is computed from the fraction of runs for which the epidemic

reaches extinction (no active infections) within the first two months after the first detected case. Error bars are

computed assuming the probability of extinction follows a binomial distribution. For mass vaccination the number

of first-dose vaccinations during the period is the same as in the combined cl. size=1 of the same scenario. **B**

Average attack rate two months after first detected case for the enhanced TTI scenario. **C** Average attack rate

two months after first detected case for the baseline TTI scenario. In panel B and C error bars are the standard

error from 8000 stochastic realisations. In all panels we assume the following parameters: R=1.2; Initial immunity

26%; 81% and 33% for 60+ and <60 already vaccinated at the beginning, respectively; no reduction in contacts

due to social distancing or teleworking. Corresponding incidence curves are reported in Figure S7 of

Supplementary Information.

Discussion

As of July 2021, social distancing and NPI intervention started to be lifted in many Western

countries owing to the decrease in COVID-19 incidence and increase in vaccination

coverage. However, cases have recently started to rise again, due to the more transmissible

Delta variant. Under these circumstances the prospects for getting back to normal are

becoming short-lived [1,26–30]. More transmissible viruses call for vaccination of a larger

proportion of the population. Vaccination must be made more accessible and able to adapt to

a rapidly evolving epidemic situation [6]. In this context, we have here analysed the reactive

vaccination of workplaces, universities and schools to assess its potential role in managing

the epidemic.

We presented an agent-based model that accounts for the key factors affecting the

effectiveness of reactive vaccination: disease natural history, vaccine characteristic, individual

contact behaviour, social distancing interventions in place and logistic constraints. Model

results suggest that: First, reactive vaccination would have a stronger impact on the COVID-

19 epidemic than non-reactive vaccination strategies, when the comparison is done at equal

number of doses within the two months. Second, combining reactive and mass vaccination

would be more effective than mass vaccination alone in both mitigating the sustained spread

and containing a flare-up in a context of diffusion of an emerging variant of concern (VOC).

Third, for the reactive strategy to be effective, vaccines should be administered quickly - i.e.

right after the detection of the first case. In addition, when the goal is to contain a flare-up,

reactive vaccination should be combined with enhanced TTI.

Reactive vaccination has been studied for smallpox, cholera and measles, among others [7–

9,31,32]. Hotspot vaccination was found to help in cholera outbreak response by both modelling

studies and outbreak investigation [32,33]. It may target geographic areas defined at spatial

resolution as diverse as districts within a country, or neighbourhoods within a city, according

to the situation. For Ebola and smallpox ring vaccination was successfully adopted to

accelerate epidemic containment [7–9]. For these infections, vaccine-induced immunity mounts

rapidly compared to the incubation period and contacts of an index case can be found before

they start transmitting since pre-symptomatic and asymptomatic transmission is almost

absent. Ring vaccination is also likely effective when the vaccine has post-exposure effects[10]

- e.g. hepatitis A, B, measles, rabies and smallpox. Reactive vaccination of schools and

university campuses has been implemented in the past to contain outbreaks of meningitis [34]

and measles [35,36].

For COVID-19, the use of reactive vaccination has been reported in Ontario, the UK,

Germany, France, among others [6,37–42]. In these places, vaccines were directed to

communities, neighbourhoods or building complexes with a large number of infections or

presenting epidemic clusters or surge of cases due to virus variants. The goal of these

campaigns was to minimise the spread of the virus, but it also addressed inequalities in

access and increased fairness, since a surge of cases may happen where people have

difficulty in isolating due to poverty and house crowding [43]. In France, reactive vaccination

was implemented to contain the emergence of variants of concerns in the municipalities of

Bordeaux, Strasbourg and Brest [40–42]. In the municipality of Strasbourg, vaccination slots

dedicated to students were created following the identification of a Delta cluster in an art

school [40]. Despite the interest in the strategy and its inclusion in the COVID-19 response

plans, very limited work has been done so far to quantify its effectiveness [44,45]. A modelling

study on ring-vaccination suggested that the strategy could be valuable if the vaccine has

post-exposure efficacy and a large proportion of contacts could be identified [45]. Still, post-

exposure effects of the vaccine remain currently under-investigated, [46] and it is likely that the

vaccination of the first ring of contacts alone would bring little benefit. We have here tested

reactive vaccination of workplaces and schools, since focusing on these settings may be an

efficient way to easily reach an extended group of contacts. Workplaces have been found to

be an important setting for COVID-19 transmission, especially specific workplaces where

conditions are more favourable for spreading [47,48]. University settings also cover a central role

in the COVID-19 transmission, due to the higher number of contacts among students,

particularly if sharing common spaces in residence accommodations [49]. Model results show

that reactive vaccination of these settings could have a stronger impact than simply

reinforcing vaccination as in hotspot strategies.

However, the feasibility and advantage of the inclusion of reactive vaccination imply a trade-

off between epidemic intensity and logistic constraints. At a high incidence level, combining

reactive and mass vaccination would substantially decrease the attack rate compared to

mass vaccination for the same number of doses, but the large initial demand in vaccines may

exceed the available stockpiles. Even with large enough stockpiles, issues like the timely

deployment of additional personnel in mobile vaccine units and the need to quickly inform the
population by communication campaigns must be solved to guarantee the success of the
campaign. We explored with the model the key variables that would impact the strategy
effectiveness. Delaying the deployment of vaccines in workplaces/schools upon the detection
of a case (from 2 to 4 days on average) would not have a strong impact on its effectiveness -
relative reduction going from 29% to 27% in Figure 3D. However, vaccines should be
deployed at the detection of the first case to avoid substantially limiting the impact of the
strategy - e.g. the relative reduction goes from 29% to 15% when workplaces/schools are
vaccinated at the detection of 5 cases (Figure 3E). At a low incidence level, the reactive
strategy would require a few extra doses in a few workplaces/schools, but the advantage with
respect to mass vaccination is overall reduced in this case.

Parameters that could greatly impact the effectiveness of reactive vaccination in containing a
flare-up of a new variant have been explored. We found that an early start of the reactive
vaccination campaign since the detection of the first VOC case was required. This requires
that tests for the detection of variants must be carried out quickly and with large coverage. In
France genomic surveillance has ramped up since the emergence of the Alpha variant in late
2020, with nationwide surveys every two weeks involving the full genome sequencing of
randomly selected positive samples [50]. Approximately 50% of positive tests are also screened
for key mutations to monitor the circulation of variants registered as VOC or VUI [50]. While
these volumes of screening may be regarded as sufficient to quickly identify the presence of
variants, the quick rising of large clusters of cases is possible, notably due to super spreading
events, becoming increasingly frequent as social restrictions relax. Second, reactive
vaccination must be part of a wider response plan, including notably a strong intensification of
TTI [51]. Rapid and efficient TTI increases the chance of epidemic containment on its own, but it
is also instrumental to the success of reactive vaccination as it allows triggering vaccination in
households, workplaces and schools. Third, an increased level of vaccine uptake is essential
for reactive vaccination to be of interest. Only 66% of the [18,65] years-old population
declared to be willing to get the vaccine in the last periodic survey by Public Health France [23].
Upward trends in vaccine uptake have been observed as the vaccination campaign unfolds,
thanks to the incentives by public health authorities, the communication effort and the strong
evidence regarding vaccine efficacy. Yet, at the time of writing only ~66% of 18+ years old
had received at least one dose [22]. As the proportion of people who declare to refuse the
COVID-19 vaccine is between 10% and 15% in France,[52] one could hope that a large
proportion of people who did not get the vaccine already would accept it if it was more
accessible, had a benefit to vaccination or received an incentive to vaccinate. An increase in
vaccine uptake was indeed observed in the context of a reactive vaccination campaign during

the course of a measles outbreak [5].Therefore reactive vaccination could be an important way

to improve access to vaccination - especially for the hard-to-reach population - and potentially

increase acceptability, e.g. due to risk perception.

The study is affected by several limitations. First, the synthetic population used in the study

accounts for the repartition of contacts across workplaces, schools, households, etc.,

informed by contact surveys. However, numbers of contacts and risk of transmission could

vary greatly according to the kind of occupation. The synthetic population accounts for this

variability assuming that the average number of contacts from one workplace to another is

gamma distributed [12]. Still, no data were available to inform the model in this respect. Second,

we model vaccination uptake according to age only, when it is determined by several

sociodemographic factors. Clusters of vaccine hesitant individuals may play an important role

in the dynamics and facilitate the epidemic persistence in the population, as it is described for

measles [53]. As vaccination coverage increases, heterogeneities in attitude toward vaccination

will likely have an increasing impact. Third, the baseline analysis is based on vaccine efficacy

parameters for the wild type virus that is best documented. Vaccine protection may be

reduced or require more time to establish with VOC infection. For example, vaccine protection

was lower for the Delta variant than for the historical variant, especially in those who had

received only one dose [54–56]. Scenarios with slower rise of vaccine protection - parametrised

from [25] - and 30% reduced efficacy against infection were tested in the sensitivity analysis.

Simulation shows a more limited impact of vaccination in this case, regardless of the strategy,

but the benefit of reactive vaccination with respect to non-reactive vaccination remains,

although reduced. Updated analyses should be done once more precise vaccine efficacy

parameters are available.

Methods

Synthetic population

We use a synthetic population for a French municipality based on the National Institute of

Statistics and Economic Studies (INSEE) censuses and French contact survey information

[12,57]. This includes the following input files: i) a setting-specific, time-varying network of daily

face-to-face contacts; ii) the maps between individuals and their age, iii) between individuals

and the household they belong to, iv) between individuals and their school, v) and between

individuals and their workplace. The synthetic population has age pyramid, household

composition, number of workplaces by size, and number of schools by type, reproducing

INSEE statistics. Daily face-to-face contacts among individuals are labelled according to the

setting in which they occur (either household, workplace, school, community or transport) and

they have assigned a daily frequency of activation, to explicitly model recurrent and sporadic

contacts. We consider the municipality of Metz in the Grand Est region, which has 117,492

inhabitants, 131 schools (from kindergarten to University) and 2888 workplaces (Figure 1A).

Detailed description of how the population was generated is provided in [12]. Information about

how to access population files is provided in the Data availability section.

Overview of the model

The model is written in C/C++, and is stochastic and discrete-time. It accounts for the

following components: (i) teleworking and social distancing, (ii) COVID-19 transmission,

accounting for the effect of the vaccine; (iii) test-trace-isolate; (iv) vaccine deployment. Model

output includes time series of incidence (clinical and subclinical cases), detailed information

on infected cases (time of infection, age, vaccination status), vaccines administered

according to the strategy, number of workplaces where vaccines are deployed. Different

epidemic scenarios are explored and compared. In the Supplementary Information we also

analyse hospitalisation entries, deaths, ICU entries, life-year lost, quality-adjusted life-year,

hospital bed and ICU bed occupancy. These quantities are computed by postprocessing

output files containing the detailed information on infected cases.

Teleworking and social distancing

To model social distancing, we assume a proportion of nodes are absent from work, modelled

by erasing working contacts and transport contacts of these nodes. We also remove a

proportion of contacts from the community layer to account for reduction in social encounters

due to closure of restaurants and other leisure activities. We choose plausible reduction

values in the range reported by google mobility reports [58] during the first half of 2021 in

France. Specifically, we set the reduction of contacts in the community to 30% within the

range of the mobility reduction in places of retail and recreation (between ~50% to ~5%)

measured from January to June 2021, and the fraction of teleworkers to 20% within the

ballpark of reduction values registered for workplaces in the same period - in general between

~35% to ~10%. Telework and social distancing is implemented at the beginning of the

simulation and remains constant for the duration of the simulation. Scenarios with no

reduction in contacts are also considered.

COVID-19 transmission model

Transmission model is an extension of the model in [12] (see Figure 1D). This accounts for

heterogeneous susceptibility and severity across age groups [59,60], the presence of an

exposed and a pre-symptomatic stage [11], and two different levels of infection outcome -

subclinical, corresponding to asymptomatic infection and pauci-symptomatic, and clinical,

corresponding to moderate to critical infection [59,61]. Precisely, susceptible individuals, if in

contact with infectious ones, may get infected and enter the exposed compartment (E). After

an average latency period ϵ^{-1} they become infectious, developing a subclinical infection (I_{sc})

with age-dependent probability p_{sc}^A and a clinical infection (I_c) otherwise. From E, before

entering either I_{sc} or I_c, individuals enter first a prodromal phase (either $I_{p,sc}$ or $I_{p,c}$), that lasts

on average μ_p^{-1} days. Compared to $I_{p,c}$ and I_c individuals, individuals in the $I_{p,sc}$ and I_{sc}

compartments have reduced transmissibility rescaled by a factor β_I. With rate μ infected

individuals become recovered. Age-dependent susceptibility and age-dependant probability

of clinical symptoms are parametrised from [59]. In addition, transmission depends on setting as

in [12]. Parameters are summarised in Table S1 of the Supplementary Information.

We model vaccination with a leaky vaccine, partially reducing both the risk of infection (i.e.

reduction in susceptibility, VE_S) and infection-confirmed symptomatic illness (VE_{SP}) [17]. Level of

protection increases progressively after the inoculation of the first dose. In our model we did

not explicitly account for the two-dose administration, but we accounted for two levels of

protection – e.g. a first one approximately in between of the two doses and a second one

after the second dose. Vaccine efficacy was zero immediately after inoculation, mounting

then to an intermediate level ($VE_{S,1}$ and $VE_{SP,1}$) and a maximum level later ($VE_{S,2}$ and $VE_{SP,2}$).

This is represented through the compartmental model in Figure 1C. Upon administering the

first dose, S individuals become, $S^{V,0}$, i.e. individuals that are vaccinated, but have no vaccine

protection. If they do not become infected, they enter the stage $S^{V,1}$ at rate ν_1, where they are

partially protected, then stage $S^{V,2}$ at rate ν_2 where vaccine protection is maximum. $S^{V,1}$ and

$S^{V,2}$ individuals have reduced probability of getting infected by a factor $r_{S,1} = (1 - VE_{S,1})$ and

$r_{S,2} = (1 - VE_{S,2})$, respectively. In case of infection, $S^{V,2}$ individuals progress first to exposed

vaccinated (E^V), then to either preclinical or pre-subclinical vaccinated ($I_{p,c}^V$ or $I_{p,sc}^V$) that are

followed by clinical and subclinical vaccinated respectively (I_c^V or I_{sc}^V). Probability of becoming

$I_{p,c}^V$ from E^V is reduced of a factor $r_{c,2} = (1 - VE_{SP,2})(1 - VE_{S,2})^{-1}$. For the $S^{V,1}$ individuals

that get infected we assume a polarised vaccine effect, i.e. they can enter either in E^V, with

probability p_V, or in E (Figure 1D). The value of p_V can be set based on $VE_{SP,1}$ through the

relation $(1 - VE_{SP,1}) = (1 - VE_{S,1})(p_V r_{c,2} + (1 - p_V))$.

Under the assumption that no serological/virological/antigenic test is done before vaccine

administration, the vaccine is administered to all individuals, except for clinical cases who

show clear signs of the disease or individuals that were detected as infected by the TTI in

place. In our model a vaccine administered to infected or recovered individuals has no effect.

In the baseline scenario we parametrise $VE_{SP,1}$ and $VE_{SP,2}$ based on the vaccine efficacies

estimated in clinical trials [18,19]. We then set and $VE_{S,1}$ and $VE_{S,2}$ by keeping the same ratio

estimated in [25]. In the sensitivity analysis we assume a more conservative hypothesis, by

calibrating the model entirely from [25]. We also explore a reduction of 30% in $VE_{S,1}$ and $VE_{S,2}$.

Parameters are listed in Table S2 of the Supplementary Information.

Test-trace-isolate

We model a baseline TTI as regularly, in place in France, accounting for case detection,

household isolation and manual contact tracing. Fifty percent of individuals with clinical

symptoms were assumed to get tested and to isolate if positive. We assume an exponentially

distributed delay from symptoms onset to case detection and its isolation with 3.6 days on

average. Once a case is detected, his/her household members isolate with probability $p_{ct,HH}$,

while other contacts isolate with probabilities $p_{ct,A}$ and $p_{ct,Oth}$, for acquaintances and sporadic

contacts, respectively. In addition to the detection of clinical cases, we assumed that a

proportion of subclinical cases were also identified (10%). Isolated individuals resume normal

daily life after 10 days unless they still have clinical symptoms after the time has passed.

They may, however, decide to drop out from isolation each day with a probability of 13% if

they do not have symptoms [62].

In the scenario of virus re-introduction, we consider enhanced TTI, corresponding to a

situation of case investigation, screening campaign and sensibilisation (prompting higher

compliance to isolation). We assume a higher detection of clinical and subclinical cases

(100% and 50% respectively), perfect compliance to isolation by the index case and

household members and a three-fold increase in contacts identified outside the household.

Step-by-step description of contact tracing is provided in the Supplementary Information.

Parameters for baseline TTI are provided in Table S3, while parameters for enhanced TTI are

provided in Table S4.

Vaccination strategies

A vaccine opinion (willingness or not to vaccinate) is stochastically assigned to each

individual at the beginning of the simulation depending on age (below/above 65). Opinion

does not change during the simulation. In some scenarios we assume that all individuals are

willing to accept the vaccine in case of reactive vaccination, while maintaining the opinion

originally assigned to them when the vaccine is proposed in the context of non-reactive

vaccination. Only individuals above a threshold age, $a_{th,V} = 18$ years old, are vaccinated. We

assume that a certain fraction of individuals is vaccinated at the beginning of the simulation

according to the age group ([18,60], 60+). We compare the following vaccination strategies:

Mass: V_{daily} randomly selected individuals are vaccinated each day until a V_{tot} limit is

reached.

Workplaces/universities: Random workplaces/universities are selected each day. All

individuals belonging to the place, willing to be vaccinated, and not isolated at home that day

are vaccinated. Individuals in workplaces/universities are vaccinated each day until the daily

limit, V_{daily} is reached. No more than V_{tot} individuals are vaccinated during the course of the

simulation. We assume that only workplaces with $size_{th} = 20$ employees or larger implement

vaccination.

School location: Random schools, other than universities, are selected each day and a

vaccination campaign is conducted in the places open to all adult household members of

school students. All household members willing to be vaccinated, above the threshold age

and not isolated at home that day are vaccinated. No more than V_{daily} individuals are

vaccinated each day and no more than V_{tot} individuals are vaccinated during the course of

the simulation.

Reactive: When a case is detected, vaccination is done in her/his household with rate r_V .

When a cluster – i.e. at least n_{cl} cases detected within a time window of length T_{cl} – is

detected in a workplace/school, vaccination is done in that place with rate r_V . In the baseline

scenario, we assume vaccination in workplace/school to be triggered by one single infected

individual ($n_{cl} = 1$). In both household and workplace/school, all individuals belonging to the

place above the threshold age and willing to be vaccinated are vaccinated. Individuals that

were already detected and isolated at home are not vaccinated. No more than V_{daily}

individuals are vaccinated each day and no more than V_{tot} individuals are vaccinated during

the course of the simulation. In the baseline scenario these quantities are unlimited, i.e. all

individuals to be vaccinated in the context of reactive vaccination are vaccinated.

Parameters and their values are summarised in Table S5 of the Supplementary Information.

Data availability

539   The synthetic population used in the analysis is available on github [63].

Code availability

541   We provide all C/C++ code files of the model on github [63].

References

1. Kiem, C. T. *et al.* Short and medium-term challenges for COVID-19 vaccination: from prioritisation to the relaxation of measures. (2021).

2. Bubar, K. M. *et al.* Model-informed COVID-19 vaccine prioritization strategies by age and serostatus. *Science* (2021) doi:10.1126/science.abe6959.

3. Matrajt, L., Eaton, J., Leung, T. & Brown, E. R. Vaccine optimization for COVID-19: Who to vaccinate first? *Science Advances* **7**, eabf1374 (2020).

4. Lu, D. *et al.* Data-driven estimate of SARS-CoV-2 herd immunity threshold in populations with individual contact pattern variations. *medRxiv* 2021.03.19.21253974 (2021) doi:10.1101/2021.03.19.21253974.

5. Le Menach, A. *et al.* Increased measles–mumps–rubella (MMR) vaccine uptake in the context of a targeted immunisation campaign during a measles outbreak in a vaccine-reluctant community in England. *Vaccine* **32**, 1147–1152 (2014).

6. Overview of the implementation of COVID-19 vaccination strategies and deployment plans in the EU/EEA. *European Centre for Disease Prevention and Control* https://www.ecdc.europa.eu/en/publications-data/overview-implementation-covid-19-vaccination-strategies-and-deployment-plans (2021).

7. Merler, S. *et al.* Containing Ebola at the Source with Ring Vaccination. *PLOS Neglected Tropical Diseases* **10**, e0005093 (2016).

8. Henao-Restrepo, A. M. *et al.* Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. *Lancet* (2015) doi:10.1016/S0140-6736(15)61117-5.

9. Geddes, A. M. The history of smallpox. *Clinics in Dermatology* **24**, 152–157 (2006).

10. Gallagher, T. & Lipsitch, M. Postexposure Effects of Vaccines on Infectious Diseases. *Epidemiologic Reviews* **41**, 13–27 (2019).

11. He, X. *et al.* Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nature Medicine* 1–4 (2020) doi:10.1038/s41591-020-0869-5.

12. López, J. A. M. *et al.* Anatomy of digital contact tracing: Role of age, transmission

setting, adoption and case detection. *Science Advances* eabd8750 (2021)

doi:10.1126/sciadv.abd8750.

13.   Ajelli, M. *et al.* Comparing large-scale computational approaches to epidemic

modeling: Agent-based versus structured metapopulation models. *BMC Infectious*

Diseases **10**, 190 (2010).

14.   Chao, D. L., Halloran, M. E., Obenchain, V. J. & Jr, I. M. L. FluTE, a Publicly

Available Stochastic Influenza Epidemic Simulation Model. *PLOS Comput Biol* **6**,

e1000656 (2010).

15.   Willem, L., Verelst, F., Bilcke, J., Hens, N. & Beutels, P. Lessons from a decade of

individual-based models for infectious disease transmission: a systematic review (2006-

2015). *BMC Infectious Diseases* **17**, 612 (2017).

16.   Liu, Q.-H. *et al.* Measurability of the epidemic reproduction number in data-driven

contact networks. *PNAS* **115**, 12680–12685 (2018).

17.   Basta, N. E., Halloran, M. E., Matrajt, L. & Longini, I. M. Estimating influenza vaccine

efficacy from challenge and community-based study data. *Am J Epidemiol* **168**, 1343–

1352 (2008).

18.   Polack, F. P. *et al.* Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.

New England Journal of Medicine **383**, 2603–2615 (2020).

19.   Baden, L. R. *et al.* Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.

New England Journal of Medicine **384**, 403–416 (2021).

20.   Proportion de la population infectée par SARS-CoV-2. https://modelisation-

covid19.pasteur.fr/realtime-analysis/infected-population/.

21.   Hozé, N. *et al.* Monitoring the proportion of the population infected by SARS-CoV-2

using age-stratified hospitalisation and serological data: a modelling study. *The Lancet*

Public Health **6**, e408–e415 (2021).

22.   Tableau de bord COVID-19. https://www.gouvernement.fr/info-coronavirus/carte-et-

donnees#vue_d_ensemble-taux_d_incidence.

23.   SPF. COVID-19 : point épidémiologique du 6 mai 2021.

https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-et-infections-

respiratoires/infection-a-coronavirus/documents/bulletin-national/covid-19-point-

epidemiologique-du-6-mai-2021.

24.   CoviPrev : une enquête pour suivre l'évolution des comportements et de la santé

mentale pendant l'épidémie de COVID-19. https://www.santepubliquefrance.fr/etudes-et-

enquetes/coviprev-une-enquête-pour-suivre-l'évolution-des-comportements-et-de-la-

sante-mentale-pendant-l-epidemie-de-covid-19.

25.   Dagan, N. *et al.* BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass

Vaccination Setting. *New England Journal of Medicine* (2021)

doi:10.1056/NEJMoa2101765.

26.   Huang, B. *et al.* Integrated vaccination and physical distancing interventions to

prevent future COVID-19 waves in Chinese cities. *Nat Hum Behav* **5**, 695–705 (2021).

27.   Moore, S., Hill, E. M., Tildesley, M. J., Dyson, L. & Keeling, M. J. Vaccination and

non-pharmaceutical interventions for COVID-19: a mathematical modelling study. *The*

Lancet Infectious Diseases **21**, 793–802 (2021).

28.   Yang, J. *et al.* Despite vaccination, China needs non-pharmaceutical interventions to

prevent widespread outbreaks of COVID-19 in 2021. *Nat Hum Behav* 1–12 (2021)

doi:10.1038/s41562-021-01155-z.

29.   Gozzi, N., Bajardi, P. & Perra, N. The importance of non-pharmaceutical interventions

during the COVID-19 vaccine rollout. *medRxiv* 2021.01.09.21249480 (2021)

doi:10.1101/2021.01.09.21249480.

30.   Bosetti, P. *et al.* Epidemiology and control of SARS-CoV-2 epidemics in partially

vaccinated populations: a modeling study applied to France. (2021).

31.   Grais, R. F. *et al.* Time is of the essence: exploring a measles outbreak response

vaccination in Niamey, Niger. *Journal of The Royal Society Interface* (2007)

doi:10.1098/rsif.2007.1038.

32.   Finger, F. *et al.* The potential impact of case-area targeted interventions in response

to cholera outbreaks: A modeling study. *PLOS Medicine* **15**, e1002509 (2018).

33.   Martin, S. *et al.* Post-licensure deployment of oral cholera vaccines: a systematic

review. *Bull World Health Organ* **92**, 881–893 (2014).

34.   Capitano, B., Dillon, K., LeDuc, A., Atkinson, B. & Burman, C. Experience

implementing a university-based mass immunization program in response to a

meningococcal B outbreak. *Human Vaccines & Immunotherapeutics* **15**, 717–724 (2019).

35.   Pegorie, M. *et al.* Measles outbreak in Greater Manchester, England, October 2012 to

September 2013: epidemiology and control. *Eurosurveillance* **19**, 20982 (2014).

36.   Kirolos, A. *et al.* Imported case of measles in a university setting leading to an

outbreak of measles in Edinburgh, Scotland from September to December 2016.

Epidemiology & Infection **146**, 741–746 (2018).

37.   Ontario's COVID-19 vaccination plan. *COVID-19 (coronavirus) in Ontario*

https://covid-19.ontario.ca/ontarios-covid-19-vaccination-plan.

38.   Covid-19: More variant hotspots to get surge tests and jabs. *BBC News* (2021).

39.   Welle (www.dw.com), D. COVID: Cologne project aims to vaccinate urban hot spots |

DW | 08.05.2021. *DW.COM* https://www.dw.com/en/covid-cologne-project-aims-to-

vaccinate-urban-hot-spots/a-57472989.

40.   COVID-19 : présence du variant indien dans l'Eurométropole et plan d'actions

immédiat. http://www.grand-est.ars.sante.fr/covid-19-presence-du-variant-indien-dans-

leurometropole-et-plan-dactions-immediat.

41.   COVID-19 : en Pays de Brest, la vaccination s'accélère.

http://www.bretagne.ars.sante.fr/covid-19-en-pays-de-brest-la-vaccination-saccelere.

42.   Communiqué de presse - Covid-19 - La nécessité de se faire vacciner rapidement

pour éviter la propagation du virus, notamment du variant delta. http://www.nouvelle-

aquitaine.ars.sante.fr/communique-de-presse-covid-19-la-necessite-de-se-faire-vacciner-

rapidement-pour-eviter-la.

43.   Valdano, E., Lee, J., Bansal, S., Rubrichi, S. & Colizza, V. Highlighting socio-

economic constraints on mobility reductions during COVID-19 restrictions in France can

inform effective and equitable pandemic response. *Journal of Travel Medicine* **28**, (2021).

44.   Xu, W., Su, S. & Jiang, S. Ring vaccination of COVID-19 vaccines in medium- and

655   high-risk areas of countries with low incidence of SARS-CoV-2 infection. *Clin Transl Med*

656   **11**, e331 (2021).

657   45.   MacIntyre, C. R., Costantino, V. & Trent, M. Modelling of COVID-19 vaccination

658   strategies and herd immunity, in scenarios of limited and full vaccine supply in NSW,

659   Australia. *Vaccine* (2021) doi:10.1016/j.vaccine.2021.04.042.

660   46.   Muller, C. P. Can integrated post-exposure vaccination against SARS-COV2 mitigate

661   severe disease? *The Lancet Regional Health – Europe* **5**, (2021).

662   47.   Althouse, B. M. *et al.* Superspreading events in the transmission dynamics of SARS-

663   CoV-2: Opportunities for interventions and control. *PLOS Biology* **18**, e3000897 (2020).

664   48.   Leclerc, Q. J. *et al.* What settings have been linked to SARS-CoV-2 transmission

665   clusters? *Wellcome Open Research* **5**, 83 (2020).

666   49.   Christensen, H. *et al.* COVID-19 transmission in a university setting: a rapid review of

667   modelling studies. *medRxiv* 2020.09.07.20189688 (2020)

668   doi:10.1101/2020.09.07.20189688.

669   50.   Coronavirus : circulation des variants du SARS-CoV-2.

670   https://www.santepubliquefrance.fr/dossiers/coronavirus-covid-19/coronavirus-circulation-

671   des-variants-du-sars-cov-2.

672   51.   Pullano, G. *et al.* Underdetection of COVID-19 cases in France threatens epidemic

673   control. *Nature* 1–9 (2020) doi:10.1038/s41586-020-03095-6.

674   52.   Spire, A., Bajos, N. & Silberzan, L. Social inequalities in hostility toward vaccination

675   against Covid-19. *medRxiv* 2021.06.07.21258461 (2021)

676   doi:10.1101/2021.06.07.21258461.

677   53.   Metcalf, C. J. E. *et al.* Seven challenges in modeling vaccine preventable diseases.

678   *Epidemics* **10**, 11–15 (2015).

679   54.   Sheikh, A., McMenamin, J., Taylor, B. & Robertson, C. SARS-CoV-2 Delta VOC in

680   Scotland: demographics, risk of hospital admission, and vaccine effectiveness. *The*

681   *Lancet* **397**, 2461–2462 (2021).

55.   Nasreen, S. *et al. Effectiveness of COVID-19 vaccines against variants of concern,*

Canada. http://medrxiv.org/lookup/doi/10.1101/2021.06.28.21259420 (2021)

doi:10.1101/2021.06.28.21259420.

56.   Investigation of SARS-CoV-2 variants of concern: technical briefings. *GOV.UK*

https://www.gov.uk/government/publications/investigation-of-novel-sars-cov-2-variant-

variant-of-concern-20201201.

57.   Béraud, G. *et al.* The French Connection: The First Large Population-Based Contact

Survey in France Relevant for the Spread of Infectious Diseases. *PLOS ONE* **10**,

e0133203 (2015).

58.   COVID-19 Community Mobility Report. *COVID-19 Community Mobility Report*

https://www.google.com/covid19/mobility?hl=en.

59.   Davies, N. G. *et al.* Age-dependent effects in the transmission and control of COVID-

19 epidemics. *Nature Medicine* 1–7 (2020) doi:10.1038/s41591-020-0962-9.

60.   Di Domenico, L., Pullano, G., Sabbatini, C. E., Boëlle, P.-Y. & Colizza, V. Modelling

safe protocols for reopening schools during the COVID-19 pandemic in France. *Nat*

Commun **12**, 1073 (2021).

61.   Riccardo, F. *et al.* Epidemiological characteristics of COVID-19 cases and estimates

of the reproductive numbers 1 month into the epidemic, Italy, 28 January to 31 March

2020. *Eurosurveillance* **25**, 2000790 (2020).

62.   Smith, L. E. *et al.* Adherence to the test, trace and isolate system: results from a time

series of 21 nationally representative surveys in the UK (the COVID-19 Rapid Survey of

Adherence to Interventions and Responses [CORSAIR] study). *medRxiv* (2020)

doi:10.1101/2020.09.15.20191957.

63.   PYB-SU. PYB-SU/ReactiveVaccination. https://github.com/PYB-

SU/ReactiveVaccination (2021).

Acknowledgements

We acknowledge financial support from Haute Autorité de Santé; the ANR and Fondation de

Supplementary Information

Additional Methods

COVID-19 transmission model

We provide here in the following the parameter values for transmission and infection natural
history (Table S1), and the effect of vaccination (Table S2). For a detailed explanation of the
transmission model without vaccination we refer to [1].

Table S1. Transmission parameters and their baseline values.

Parameter	Description	Value	Source
IP	Incubation period	5.2 days	[2]
μ_p	Rate of developing symptoms for pre-symptomatic individuals	$(2.3 \text{ days})^{-1}$	[3]
ϵ	Rate of becoming infectious for exposed individuals	$(2.9 \text{ days})^{-1}$	$IP - \mu_p^{-1}$
μ	Recovery rate	$(7 \text{ days})^{-1}$	[3]
β_I	transmissibility rescaling according to the infectious stage	0.51 for $I_{p,sc}, I_{sc}$ 1 for $I_{p,c}, I_c$	[4]
ω_s	Transmission risk by setting (network layer)	1 for H layer 0.3 for C layer 0.5 otherwise	[1]

723 **Table S2. Vaccine efficacy parameters and their baseline values.**

Parameter	Description	Baseline value	Source
$r_{S,1}$	reduction in susceptibility in the partial-protection stage	0.48	from $VE_S = 52\%$ estimated at 7 days from the first dose in [5,6]
ν_1	Rate of developing partial protection after vaccine uptake	$(1 \text{ week})^{-1}$	[5,6]

$r_{S,2}$	reduction in susceptibility in the maximum-protection stage	0.13	from $VE_S = 87\%$ estimated at 14 days from the first dose in [5,6]
$r_{c,2}$	reduction in the probability of developing clinical symptoms in the maximum-protection stage	0.76	from $VE_{SP} = 90\%$ estimated at one week after the second dose, i.e. 28 days after first dose [5,6]
v_2	Rate of developing maximum protection after entering the partial-protection stage	(1 week)$^{-1}$	One week after the second dose, i.e. 14 days after first dose [5,6]
p_V	Probability of transition between $S^{V,1}$ and E^V	0.86	Computed from the parameters above and $VE_{SP} = 62\%$ estimated at 7 days from the first dose in [5,6]

Test-trace-isolate

We model case detection and isolation, combined with tracing and isolation of contacts
according to the following rules:

● As an individual shows clinical symptoms, s/he is detected with probability $p_{d,c}$. If
detected, case confirmation and isolation occur with rate r_d upon symptoms onset.

● Subclinical individuals are also detected with probability $p_{d,sc}$, and rate r_d .

● The index case's household contacts are isolated, with probability $p_{ct,HH}$, the same time
the index case is detected and isolated. We assume that these contacts are tested at the
time of isolation and among those all subclinical, clinical, pre-subclinical, and pre-clinical
cases are detected (testing sensitivity 100%).

● Once the index case is detected, contacts of the index case occurring outside the
household are traced and isolated with an average delay r_{ct}^{-1}. We define an acquaintance
as a contact occurring frequently, i.e. with a frequency of activation higher than f_a. We
assume that an acquaintance is detected and isolated with a probability $p_{ct,A}$, while other
contacts (i.e. sporadic contacts) are detected and isolated with probability $p_{ct,sp}$, with
$p_{ct,A} > p_{ct,sp}$. We assume that traced contacts are tested at the time of isolation and
among those all subclinical, clinical, pre-subclinical, and pre-clinical cases are detected
(testing sensitivity 100%).

• Only contacts (among contacts occurring both in household and outside) occurring within
a window of D days before index case detection are considered for contact tracing.

• The index-case and the contacts are isolated for a duration d_I (for all infected
compartments) and d_{NI} (for susceptible and recovered compartments). Contacts with no
clinical symptoms have a daily probability p_{drop} to drop out from isolation.

• For both the case and the contacts, isolation is implemented by assuming no contacts
outside the household and transmission risk per contact within a household reduced by a
factor ι.

Parameter values are reported in Table S3 and Table S4 for baseline and enhanced TTI,
respectively.

Table S3. Model for test-trace-isolation. Parameters and their values for the baseline case.

Parameter	Description	Value	Source
$p_{d,c}$	Probability that a clinical case is detected	0.5	
$p_{d,sc}$	Probability that a subclinical case is detected	0.1	
r_d	For detected cases, rate of detection, confirmation and beginning of isolation	0.28 = (3.6 days)$^{-1}$	Average time from onset to testing is 2.6 days [7]. We assume one day to have the test results.
D	Length of the period preceding index-case confirmation, used to define a contact	6 days (*)	$\simeq 2$ days $+ r_d^{-1}$ (a person is considered to be contact if s/he entered in contact with the index case during a window of 2 days preceding symptoms onset)
$p_{ct,HH}$	Probability that household contacts of an index case are identified and decide to isolate	0.7	
$p_{ct,A}$	Probability that acquittances of an index case are identified and decide to isolate	0.08	Calibrated to get $\simeq 2.8$ contacts per index case on average (assumed $p_{ct,Oth} = p_{ct,A}/10$) [7]

$p_{ct,Oth}$	Probability that the contacts of a detected case outside household are compliant to isolation	0.008	Calibrated to get $\simeq 2.8$ contacts per index case on average (assumed $p_{ct,Oth} = p_{ct,A}/10$) [7]
r_{ct}	Rate of detection and isolation of contacts outside household	0.9 = (1.1 days)$^{-1}$	
f_a	Threshold frequency to define a contact as an acquaintance	1/7 days	
p_{do}	Probability to drop out from isolation for individuals that are not clinical	0.13	[8]
ι	Reduction in household transmission during isolation	0.5	
d_{NI}, d_I	Duration of isolation for an individual that is not infectious, duration of isolation for an individual that is infectious	10 days, 10 days	[9]

755 **Table S4. Model for test-trace-isolation. Parameters and their values for the case of enhanced TTI. Only**
756 **values different from the baseline case are reported.**

Parameter	Description	Value
$p_{d,c}$	Probability that a clinical case is detected	1
$p_{d,sc}$	Probability that a subclinical case is detected	0.5
r_d	For detected cases, rate of detection, confirmation and beginning of isolation	0.9 = (1.1 days)$^{-1}$
$p_{ct,HH}$	Probability that household contacts of an index case are identified and decide to isolate	1
$p_{ct,A}$	Probability that acquittances of an index case are identified and decide to isolate	0.24
$p_{ct,Oth}$	Probability that the contacts of a detected case outside household are compliant to isolation	0.024

p_{do}	Probability to drop out from isolation for individuals that are not clinical	0	

Vaccination strategies

759 We provide here in the following the parameters values for the vaccination strategies detailed
760 in the Methods section of the main paper.

761 **Table S5. Vaccine administering. Parameters and their baseline values.**

Parameter	Description	Baseline values (other explored values)	Source
$a_{th,V}$	Minimum age for vaccination	18 years	
P_V^a	Probability an individual is willing to vaccinate	90% for 65+ 66% for <65	10
n_{cl}	For reactive vaccination, cluster size for triggering reactive vaccination in a workplace	1 (2, 3, 4, 5)	
T_{cl}	For reactive vaccination, time window for cluster definition	7 days	
$(r_V)^{-1}$	For reactive vaccination, delay of implementation of the vaccination campaign once the cluster is identified (for workplaces/schools) and a case is identified (for households)	2 days (1 day, 4 days)	
V_{TOT}	Maximum number of people vaccinated during one simulation	Unlimited	
V_{day}	Maximum number of people vaccinated each day	[85, 511] per 100,000 inhabitants per day for Mass, workplaces/universities, school location Unlimited for reactive ([85, 511] per 100,000 inhabitants per day)	
$size_{th}$	For WP/U, minimum size of a workplace that implement vaccination	20	

Details on the epidemic simulations

A schematic representation of the main program and of the simulation code and of the algorithm used for a single stochastic realisation are shown in Figure S1 and S2, respectively. Simulations are discrete-time and stochastic. At each time step, corresponding to one day, three processes occur (Figure S2):

vacciantionStep: vaccines are administered according to the strategy or the strategies' combination.

testingStep: cases are detected and isolated; contacts (within and outside household) are identified and isolated; isolated individuals get out from isolation.

transmissionStep: infectious status of nodes is updated. This includes transmission, recovery and transition through the different stages of the infection (e.g. from exposed to pre-symptomatic, from pre-symptomatic to symptomatic)

A single-run simulation is executed with no modelled intervention, until the desired immunity level is reached. This guarantees that immune individuals are realistically clustered on the network. We added some noise, by reshuffling the immune/susceptible status of 30% of the nodes to account for travelling, infection reintroduction from other locations and large gathering with consequent super-spreading not accounted for by the model. In Figure 2 and 3 of the main paper, all processes (transmission, TTI, vaccination) are simulated from the beginning of the simulation. In the scenario with virus re-introduction (Figure 4), TTI and mass vaccination are modelled from the beginning. TTI is enhanced from the detection of the first case. Reactive vaccination starts after the detection of the first n_{RV} cases, with $n_{RV} = 1,5,10$ explored.

We vary COVID-19 transmission potential by tuning the daily transmission rate per contact β. The reproductive number R is computed numerically as the average number of infections each infected individual generates throughout its infectious period at the beginning of the simulation. We tune β to have the desired R value (1.2 for the analysis in the main text) for the reference scenario - i.e. with only vaccination at the start. We then compare different vaccination strategies at the same value of transmissibility β.

Figure S1: Algorithm of the main program. (drawn with code2flow.com)

795 Figure S2: Algorithm for one stochastic realisation. (drawn with code2flow.com)

Additional Results

Comparison between reactive and non-reactive vaccination strategies: sensitivity analysis

We compare here reactive vaccination with non-reactive vaccination strategies under a
variety of epidemic scenarios.

The impact of reactive vaccination and its demand in terms of vaccine doses varies

depending on the incidence level. Figure S3 compares reactive and workplaces/universities

vaccination in scenarios with variable initial incidence. As initial incidence increases the

reduction in the attack rate due to workplaces/universities vaccination diminishes, while the

one due to reactive vaccination slightly increases. Therefore, the advantage of the reactive

vaccination compared with the other strategy increases. This is explained by the dynamic

adaptation of reactive vaccination to the epidemic situation: the higher the incidence is, the

more vaccines are deployed.

Figure S3 Attack rate (AR) relative reduction (RR) after two months according to the initial incidence for reactive

and workplaces/universities vaccination with 200 and 500 new vaccinated daily. The size of the points is

proportional to the average daily vaccination rate during the period.

Figure S4 shows how the relative reduction of the attack rate after two months changes with

transmission, immunity level of the population, fraction of adults initially vaccinated, reduction

in contacts due to social distancing, vaccine efficacy and time needed for the vaccine to

become effective. Here we consider the high incidence scenario (Figure 2A-C of the main

paper) and we compare mass and reactive strategies assuming the same vaccine uptake.

Increasing the transmissibility (panel A) has no significant effect on the efficacy of vaccination

for all strategies considered. Panel B and C show that decreasing the initial proportion of

susceptible, due to increasing either natural immunity or initial vaccination coverage, reduces

the impact of all vaccination strategies. In particular, reactive vaccination has a limited effect

when the initial vaccination coverage is high, as the number of people remaining to vaccine is

limited. In panel D we explore the impact of teleworking and reduction in community contact

by comparing the baseline scenario with a scenario with no restrictions. Impact of non-

reactive vaccination strategies remains almost unaltered. However, reactive vaccination

becomes more effective when no restriction is in place. This is likely due to the enhanced role

of workplaces as a setting of transmission when no teleworking is in place, thus bringing to an

increased benefit of reactive vaccination targeting this setting. In panel E, we explore a

different hypothesis regarding the effect of vaccination assuming more time for the vaccine

protection to mount after inoculation. Specifically, we use the parametrisation of [11], with $r_{S1} =$

0.54, $r_{S2} = 0.08$ and $v_1 = v_2 = (14\ days)^{-1}$. As expected, this change reduces the impact of

the vaccination campaign. Still, reactive vaccination outperforms mass vaccination at an

equal number of first-dose vaccination. This result remains valid also when assuming a 30%

reduction in the vaccine effectiveness in susceptibility with respect to baseline values (panel

F).

Figure S4. Attack rate (AR) relative reduction (RR) after two months. RR is computed with respect to the reference

scenario where only initial vaccination is in place. We consider the high incidence scenario, with initial incidence of

clinical cases 160 per 100,000 inhabitants, and we compare the reactive vaccination (points) with the mass

vaccination, with 85, 255 and 426 vaccines per 100 000 inhabitants per day (bars). Explored parameters are: the

reproduction number (A); initial immunity level (B); initial vaccination coverage among 18-60 y.o. People (C);

presence/absence of teleworking and contact restriction in the community (D); time needed for the vaccine to

become effective (E), vaccine efficacy in susceptibility (F). Except when otherwise indicated, parameters are the
same as in Figure 2A of the main text.

Comparison between reactive and non-reactive vaccination strategies: additional epidemic outcomes

Based on the estimated incidence of clinical cases per day provided by the transmission
model, we infer outcomes related to hospital, namely hospital and intensive care unit (ICU)
entries, beds in ICU ward, and deaths. We use age-dependent hospital admissions (ICU and
non-ICU) risks estimated by [12,13] and ICU admission risks for hospitalised patients based on
SI-VIC extract [14]. Hospital admissions risks were adjusted to apply only to clinical cases [15]
and to account for vaccine efficacy for hospitalisation for no vaccination, after one week from
vaccine inoculation, and after two weeks from vaccine inoculation [11]. Patients who were
hospitalised entered the hospital on average 7 days (sd = 3.9 days – Gamma distribution)
after the beginning of the infectious phase [16]. Those who were admitted in ICU enter this unit
with a mean delay of 1.69 days (assuming an exponential distribution) [14]. To estimate the
number of occupied beds, we use age-specific mean durations of stay and their
corresponding standard deviations in ICU calculated on all the hospitalised cases in the first 9
months of the French epidemic (March-November 2020)[14]. We assume that the standard
deviations of ICU lengths of stay were equal to the corresponding mean and do not consider
post-ICU care in the estimation of occupied beds. We estimate the number of deaths using
hospital and ICU death risks of hospitalised infected persons [14]. Deaths are delayed in time
using the mean delays and standard deviations from hospital or ICU admission to death [14]. All
lengths of stay are supposed to follow a Gamma distribution. Parameters and their values are
summarised in Tables S6 and S7.

We also estimate the number of life years and quality-adjusted life years (QALY) lost for each
death using life-tables provided by 'French National Institute of Statistics and Economic
Studies' (INSEE) for 2012-2016 [17] and utility measures of each age-group in France [18].

**Table S6. Risks of hospitalisation according to vaccination status, ICU admission and death in general
ward and ICU**

Age Group	Hospitalisation risk for no-vaccination	Hospitalisation risk for half vaccination (1 dose)	Hospitalisation risk for full vaccination	ICU admission risk	Death risk in general ward	Death risk in ICU

	n (2 doses)					
0-9	0,0098	0,0059	0,0211	0,159	0,006	0,078
10-19	0,0054	0,0033	0,0117	0,159	0,006	0,078
20-29	0,0144	0,0087	0,0313	0,159	0,006	0,078
30-39	0,0176	0,0106	0,0381	0,159	0,006	0,078
40-49	0,0245	0,0148	0,0531	0,219	0,016	0,103
50-59	0,0673	0,0407	0,1459	0,270	0,030	0,175
60-69	0,0937	0,0566	0,2029	0,299	0,064	0,268
70-79	0,2029	0,1227	0,4396	0,235	0,140	0,366
79+	0,3768	0,2278	0,8164	0,053	0,308	0,468

875 **Table S7. Delays from hospitalisation admission in general ward to death or hospital discharge and delays**
876 **from ICU admission to ICU discharge or death.**

Age Group	Mean los in general ward (sd)	Mean los in general ward for dying people (sd)	Mean los in ICU (sd)	Mean los in ICU for dying people (sd)
0-9	6,4 (6,8)	10,6 (12,3)	12,7 (12,7)	22,3 (22,3)
10-19	6,4 (6,8)	10,6 (12,3)	12,7 (12,7)	22,3 (22,3)

20-29	6,4 (6,8)	10,6 (12,3)	12,7 (12,7)	22,3 (22,3)
30-39	6,4 (6,8)	10,6 (12,3)	12,7 (12,7)	22,3 (22,3)
40-49	6,4 (6,8)	10,6 (12,3)	12,7 (12,7)	22,3 (22,3)
50-59	6,4 (6,8)	10,6 (12,3)	12,7 (12,7)	22,3 (22,3)
60-69	9,3 (9,1)	10,6 (12,3)	16,7 (16,7)	20,8 (20,8)
70-79	11,7 (11,4)	10,6 (12,3)	17,5 (17,5)	18,9 (18,9)
79+	15 (13,8)	10,6 (12,3)	13,6 (13,6)	10,6 (10,6)

Los: Length of stay. Sd = Standard deviation.

Figure S5 shows the relative reductions in the number of hospitalisations, deaths, ICU

entries, life-year lost, quality-adjusted life-year lost and ICU bed occupancy at the peak,

comparing each vaccination scenario with the reference scenario - i.e. vaccination only at the

start. We consider here the high incidence scenario and vaccination strategies are compared

at the same vaccine uptake, analogously to Figure 2A of the main paper. The six indicators

show a behaviour similar to incidence. Overall reduction values are smaller. This is expected,

since a large proportion of elderly are already vaccinated at the start, and the compared

vaccination strategies target a population that is less at risk of severe infection. Still all

indicators show the same qualitative behaviour, with reactive vaccination outperforming the

non-reactive vaccination strategies at equal number of first-dose vaccination.

Figure S5. A, B, C, D, E Relative reduction (RR) in the cumulative incidence of hospitalisations, intensive care unit
(ICU) entries, deaths, life years (LY) lost and quality-adjusted life years (QALY) lost over the first two months for all
strategies as a function of the vaccination rhythm. F Relative reduction (RR) in occupied ICU beds at the peak
over the first two months for all strategies as a function of the average daily number of new vaccinated for the high
incidence scenario. In all cases we assumed the following parameters: R=1.2; Initial immunity 26%; vaccinated at
the beginning are 81% and 13% of 60+ and <60, respectively; teleworking 20% and reduction in contacts in the
community 30%; initial incidence 160 per 100,000 inhabitants.

Combined reactive and mass vaccination for managing sustained COVID-19

spread: additional results

In Figure S6 we show the incidence curve corresponding to the scenarios analysed in Figure
3A of the main paper. Mass and combined vaccination with the three different vaccination
paces are compared.

905 Figure S6 Incidence of clinical cases for mass and combined vaccination strategies for three different vaccination
906 paces. Scenarios are the same as the ones plotted in Figure 3A. We assumed the following parameters: initial
907 incidence of clinical cases 160 per 100 000 inhabitants; R=1.2; Initial immunity 26%; vaccinated at the beginning
908 are 81% and 13% of 60+ and <60, respectively; teleworking 20% and reduction in contacts in the community 30%.
909 Values are means over 2000 stochastic simulations, error bars are not displayed for the sake of visualisation.

Combined reactive and mass vaccination for managing a COVID-19 flare-up: additional results

Combined reactive and mass vaccination for managing a COVID-19 flare-up:
additional results

In Figure S7 we show the incidence curve corresponding to the scenarios analysed in Figure
4 of the main paper. Mass and combined vaccination with the different vaccination scenarios
considered are compared.

Figure S7 Incidence of clinical cases for mass and combined vaccination strategies for the scenarios analysed in
Figure 4 of the main paper. Left: scenario with enhanced TTI. Right: scenario with baseline TTI. In all panels we
assumed the following parameters: R=1.2; Initial immunity 26%; 81% and 33% of 60+ and <60 already vaccinated
at the beginning, respectively; no reduction in contacts due to social distancing and teleworking. We assume a
flare-up of cases with 3 cases initially introduced in the population.

References

1. López, J. A. M. *et al.* Anatomy of digital contact tracing: role of age, transmission setting,

adoption and case detection. *medRxiv* 2020.07.22.20158352 (2020)

doi:10.1101/2020.07.22.20158352.

2. Li, Q. *et al.* Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected

Pneumonia. *New England Journal of Medicine* **0**, null (2020).

3. He, X. *et al.* Temporal dynamics in viral shedding and transmissibility of COVID-19.

Nature Medicine 1–4 (2020) doi:10.1038/s41591-020-0869-5.

4. Di Domenico, L., Pullano, G., Sabbatini, C. E., Boëlle, P.-Y. & Colizza, V. Impact of

lockdown on COVID-19 epidemic in Île-de-France and possible exit strategies. *BMC*

Medicine **18**, 240 (2020).

5. Polack, F. P. *et al.* Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *New*

England Journal of Medicine **383**, 2603–2615 (2020).

6. Baden, L. R. *et al.* Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *New*

England Journal of Medicine **384**, 403–416 (2021).

7. SPF. COVID-19 : point épidémiologique du 6 mai 2021.

https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-et-infections-

respiratoires/infection-a-coronavirus/documents/bulletin-national/covid-19-point-

epidemiologique-du-6-mai-2021.

8. Smith, L. E. *et al.* Adherence to the test, trace and isolate system: results from a time

series of 21 nationally representative surveys in the UK (the COVID-19 Rapid Survey of

Adherence to Interventions and Responses [CORSAIR] study). *medRxiv* (2020)

doi:10.1101/2020.09.15.20191957.

9. Info Coronavirus COVID-19 - Tester - Alerter - Protéger. *Gouvernement.fr*

https://www.gouvernement.fr/info-coronavirus/tests-et-depistage.

10.   CoviPrev : une enquête pour suivre l'évolution des comportements et de la santé

mentale pendant l'épidémie de COVID-19. https://www.santepubliquefrance.fr/etudes-et-

enquetes/coviprev-une-enquête-pour-suivre-l'évolution-des-comportements-et-de-la-

sante-mentale-pendant-l-epidemie-de-covid-19.

11.   Dagan, N. *et al.* BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass

Vaccination Setting. *New England Journal of Medicine* (2021)

doi:10.1056/NEJMoa2101765.

12.   Kiem, C. T. *et al.* Short and medium-term challenges for COVID-19 vaccination: from

prioritisation to the relaxation of measures. (2021).

13.   Lapidus, N. *et al.* Do not neglect SARS-CoV-2 hospitalization and fatality risks in the

middle-aged adult population. *Infectious Diseases Now* **51**, 380–382 (2021).

14.   Lefrancq, N. *et al.* Evolution of outcomes for patients hospitalised during the first 9

months of the SARS-CoV-2 pandemic in France: A retrospective national surveillance

data analysis. *The Lancet Regional Health – Europe* **5**, (2021).

15.   Davies, N. G. *et al.* Age-dependent effects in the transmission and control of COVID-

19 epidemics. *Nature Medicine* 1–7 (2020) doi:10.1038/s41591-020-0962-9.

16.   Salje, H. *et al.* Estimating the burden of SARS-CoV-2 in France. *Science* (2020)

doi:10.1126/science.abc3517.

17.   Tables de mortalité par sexe, âge et niveau de vie − Tables de mortalité par niveau

de vie | Insee. https://www.insee.fr/fr/statistiques/3311422?sommaire=3311425.

18.   Chevalier, J. & de Pouvourville, G. Valuing EQ-5D using time trade-off in France. *Eur*

J Health Econ **14**, 57–66 (2013).